Membrane and synaptic effects of anti-s-100 are prevented by the same antibodies in low concentrations

Oi, Epstein; Beregovoy, A; Ns, Sorokina; Mv, Starostina; Mb, Shtark; KhL, Gaĭnutdinov; TKh, Gaĭnutdinova; Di, Muhamedshina

doi:10.2741/1025

Cited by 16 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mechanism of action of HD is based on their ability to induce conformational changes of the original substance/target molecule 16 . The modifying effect of HD Abs to S100 has been demonstrated in experimental studies 17 – 27 .…”

Section: Introductionmentioning

confidence: 92%

RETRACTED ARTICLE: The randomized clinical trial results of the anxiety treatment in patients with somatoform dysfunction and neurotic disorders

Парфенов

Камчатнов

Хасанова

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The existing treatments for somatoform dysfunction (SfD), reaction to severe stress (RSS), and adjustment disorders (AjD) are insufficiently effective and safe. Anxiolytic drug Tenoten proved effective in clinical trials (CT). The aim of this multicenter double-blind placebo-controlled randomized CT was to investigate the safety and efficacy of Tenoten in the treatment of anxiety in adults with SfD, RSS, AjD and other neurotic disorders (oNDs). 390 adult patients with SfD, RSS and AjD or oNDs with the Hospital Anxiety and Depression scale-anxiety (HADS-A) score ≥ 11 were randomized into 4 groups (n = 127 in Tenoten group 1 (4 tablets/day); n = 131 in Tenoten group 3 (8 tablets/day), n = 132 in combined Placebo group 2 + 4). The changes from baseline in the mean Hamilton Anxiety Rating Scale (HAM-A) score in groups 1 and 3 after 12 weeks were the primary outcome. The decrease of the HAM-A score from 18.81 ± 5.81 to 7.26 ± 4.63 (in group 1) and from 18.38 ± 4.3 to 6.40 ± 4.02 (in group 3) was observed post-treatment (pgroup 1/placebo = 0.0055, pgroup 3/placebo < 0.0001). Overall, 46 adverse events (28 in the Tenoten groups and 18 in the Placebo) were reported without any difference between the study groups. Tenoten performed significantly more effective than placebo in the anxiety treatment of adults with SfD, RSS, AjD and oNDs (clinicaltrials.gov NCT03036293).

show abstract

Section: Introductionmentioning

confidence: 92%

RETRACTED ARTICLE: The randomized clinical trial results of the anxiety treatment in patients with somatoform dysfunction and neurotic disorders

Парфенов

Камчатнов

Хасанова

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Для тенотена уже была показана способность влиять на си-наптическую пластичность и электрические характери-стики мембраны изолированных нейронов [20][21][22]; ГАМК-А-и ГАМК-Б-модулирующее действие, а также влияние на серотонинергическую систему [9,23,24]. Ней-ропротективные свойства препарата были доказаны [10] на модели нейродегенеративного заболевания, вызванно-го введением скополамина -показаны ноотропный и антиамнестический эффекты РА АТ S100, сравнимые по выраженности с действием пирацетама.…”

Section: Discussionunclassified

Antiamnesic effects divaza and its component model β-amyloid amnesia

Ganina

Duginа

Жавберт

et al. 2016

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Болезнь Альцгеймера (БА) является одним из наибо-лее социально значимых заболеваний, которому, как пра-вило, подвержены лица старшей возрастной группы. При БА отмечается комплексное нарушение структуры и функции мозга: дисфункция базальной холинергической системы, нарушение синаптической пластичности, уменьшение численности нейронов. Дисфункция базаль-ной холинергической системы заключается в том, что в аксонах холинергических нейронов, оказавшихся в зоне *e-mail: tanaevakk@materiamedica.ru накопления растворимых олигомеров бета-амилоида (но-вая кора, гиппокамп, миндалина), развивается затухаю-щая ретроградная нейропатия [1]. Она проявляется нару-шением ремоделирования терминалей аксонов, ослабле-нием синтеза, транспорта и усилением обратного захвата ацетилхолина в нейронах базальной холинергической си-стемы. Нарушение синаптической пластичности в ука-занных зонах приводит к ослаблению долговременной потенциации синаптического проведения и усилению его Цель исследования. Проверка предположения, что препарат диваза, состоящий из релиз-активных антител (РА АТ) к белку S100 и NO-синтетазе (eNOS), может обладать антиамнестическим действием. Материал и методы. Исследование проводили на модели амнезии, вызванной интрацеребровентрикулярной инъекцией фрагмента β-амилоидного пептида 25-35 крысам. Оценивали способность РА АТ к белку S100 (тенотен) и eNOS (импаза) их комбинации -дивазы компенсировать поведенческие отклонения в тестах распознавания новых объектов и условной реакции пассивного избегания. Результаты. Под влиянием РА АТ к S100 наблюдалось восстановление нарушенной кратковременной памяти, РА АТ к eNOS были более эффективны в более позднем периоде (через 24 часа). Комбинированный препарат полностью компенсировал смоделированные нарушения. Кроме того, если тенотен оказывал максимальное влияние на когнитивные функции, то импаза больше действовала на эмоциональную составляющую. Диваза оказывала более эффективное влияние на амнезию, при этом сочетая свойства обоих компонентов и взаимно усиливая их. Заключение. Полученные данные подтверждают перспективность дальнейшего исследования релиз-активных препаратов при нейродегенеративных нарушениях.Ключевые слова: амнезия, болезнь Альцгеймера, диваза, импаза, тенотен. Objective. On amnesia models induced by (icv) injection of β-amyloid fragment 25-35 peptide were evaluated antiamnestic actitity. Material and methods. It was used of active antibody preparations (RA AT) to protein S100 (tenoten), to eNOS (impaza) and combinations (divaza) antiamnestic activity behavioral tests novel object conditioned response passive avoidance. Results. Under the influence of RA AT S100 observed recovery of violation of the β-amyloid short-term memory (1 hour after the initial presentation of objects), and RA AT eNOS were more effective when tested 24 hours later. Combined medication completely compensate for the simulated deflection behavior of rats did not differ from the intact control. The CRPA RA AT S100 had the greatest impact on the LP entry into the dark compartment, and RA AT eNOS i...

show abstract

“…The mechanism of action of HD is based on their ability to induce conformational changes of the original substance/target molecule [16]. The modifying effect of HD Abs to S100 has been demonstrated in experimental studies [17][18][19][20][21][22][23][24][25][26][27].…”

Section: Introductionmentioning

confidence: 99%

The Treatment of Anxiety in Patients with Somatoform Dysfunction, Reaction to Severe Stress and other Neurotic Disorders: A Multicenter Double-blind Placebo-controlled Randomized Trial

Парфенов

Камчатнов

Амелин

et al. 2021

Preprint

View full text Add to dashboard Cite

The existing treatment of somatoform dysfunction (SD), reaction to severe stress (RSS) and adjustment disorders (AjD) is insufficiently effective and safe. Anxiolytic drug Tenoten (Materia Medica Holding) is shown to be effective in clinical trials (CT). Objectives The aim of multicenter double-blind placebo-controlled randomized CT was to investigate the safety and efficacy of Tenoten in the anxiety treatment of adults with SD, RSS, AjD and other neurotic disorders (oNDs). Methods 390 adults with SD, RSS and AjD or oNDs with the Hospital Anxiety and Depression scale-anxiety (HADS-A) score≥11 were randomized into 4 groups (Tenoten group 14 tablets/day n=127; Tenoten group 3 8 tablets/day n=131, combined Placebo group 2+4 n= 132). The changes from baseline in the mean Hamilton Anxiety Rating Scale (HAM-A) score in groups 1 and 3 after 12 weeks was the primary outcome. Results The decrease in the HAM-A score from 18.81±5.81 to 7.26±4.63 (group 1) and from 18.38±4.3 to 6.40±4.02 (group 3) was observed post-treatment (p group 1/placebo =0.0055, p group 3/placebo <0.0001). The mean changes in the scores in the groups 1, 3 and the Placebo were 11.25, 11.91 and 9.71, respectively. In total, 46 AEs (28 AEs in the Tenoten groups, 18 in the Placebo) were registered in 37 patients (20 in the Tenoten groups, and 17 in the Placebo). No differences in frequency of AEs between groups were found. Conclusions Tenoten was shown to be significantly more effective than placebo in the anxiety treatment of adults with SD, RSS, AjD and oNDs (clinicaltrials.gov NCT03036293).

show abstract

Membrane and synaptic effects of anti-s-100 are prevented by the same antibodies in low concentrations

Cited by 16 publications

References 16 publications

RETRACTED ARTICLE: The randomized clinical trial results of the anxiety treatment in patients with somatoform dysfunction and neurotic disorders

RETRACTED ARTICLE: The randomized clinical trial results of the anxiety treatment in patients with somatoform dysfunction and neurotic disorders

Antiamnesic effects divaza and its component model β-amyloid amnesia

The Treatment of Anxiety in Patients with Somatoform Dysfunction, Reaction to Severe Stress and other Neurotic Disorders: A Multicenter Double-blind Placebo-controlled Randomized Trial

Contact Info

Product

Resources

About